From Respiratory Imaging to AI Diagnostics: How 4DMedical (ASX:4DX) Is Building a Global Healthcare Platform?

Aditi Sarkar

20 August 2026 06:41 PM AEST

From Respiratory Imaging to AI Diagnostics: How 4DMedical (ASX:4DX) Is Building a Global Healthcare Platform?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

4DMedical (ASX:4DX) closed at AUD 4.02, up 6.07% on 20 August 2026.
The company develops AI-powered respiratory imaging technology for lung diagnosis and monitoring.
FY26 Operating Revenue reached AUD 7.2 million, up 23% compared with the prior corresponding period.
Investors continue to monitor CT:VQ commercialisation, global site expansion, clinical partnerships and regulatory progress.

4DMedical Limited (ASX:4DX) shares closed at AUD 4.02, up 6.07% on 20 August 2026. The movement reflects a positive Trading session as investors continue to assess the company’s respiratory imaging technology platform, commercial rollout progress and global expansion strategy.

Daily share price movements can reflect changes in investor sentiment, trading activity, valuation expectations and broader market conditions. However, a single-session movement does not necessarily indicate a change in the company’s underlying fundamentals, financial position or long-term operating outlook.

4DMedical develops medical imaging software designed to provide quantitative insights into lung structure and function. The company’s technology uses Artificial Intelligence (AI) and advanced imaging analytics to support respiratory disease diagnosis, treatment planning and monitoring.

The broader Australian market closed higher on the day. The S&P/ASX 200 (ASX:XJO) closed at 9,083.80 points, up 0.33% today, while the S&P/ASX 300 (ASX:XKO) closed at 9,019.90 points, up 0.37% today. Within the healthcare sector, the S&P/ASX 200 Health Care (ASX:XHJ) closed at 32,044.30 points, up 1.39% today.

AI-powered respiratory imaging platform

4DMedical operates within the medical technology sector, focusing on respiratory imaging solutions delivered through a Software-as-a-Service (SaaS) model.

The company’s technology platform converts conventional imaging data into functional lung insights, supporting clinicians, hospitals and research organisations. Its product suite includes XV Lung Ventilation Analysis Software (XV LVAS), CT LVAS and CT:VQ solutions.

Investors generally assess medical technology companies through commercial adoption, regulatory approvals, reimbursement progress, clinical validation, customer expansion and Recurring Revenue growth.

Unlike traditional medical device companies that rely primarily on hardware sales, 4DMedical’s SaaS-based approach aims to create recurring revenue through healthcare site subscriptions and scan-based usage.

The respiratory healthcare market continues to focus on earlier detection and more precise monitoring of lung conditions. Companies operating in this space are generally monitored for clinical adoption, healthcare system integration and the ability to translate technology development into commercial outcomes.

Commercial progress and investor focus

4DMedical’s June 2026 quarter update highlighted continued commercial expansion of its respiratory imaging platform. The company reported FY26 operating revenue of AUD 7.2 million, up 23% compared with the prior corresponding period, supported by increased paid scan volumes, including CT:VQ scans.

The company reported that its SaaS products were deployed across 540 sites globally, excluding SimonMed Imaging, representing a 39% increase year-on-year. During Q4 FY26, 4DMedical recorded 105,970 scans, up 43% compared with the prior corresponding period.

A key development was the commercial agreement with SimonMed Imaging, a US outpatient radiology network operating more than 170 imaging centres across 10 states. Under the three-year agreement, SimonMed is deploying CT:VQ and LDAf solutions with commercial terms based on per-scan pricing.

4DMedical also completed the Acquisition of European lung imaging AI company contextflow after receiving required approvals. The acquisition expanded the company’s European commercial, product development and regulatory capabilities while adding lung cancer screening and incidental findings technologies.

The company reported a cash balance of AUD 278 million as at 30 June 2026, providing funding capacity for commercialisation activities, Research and Development and expansion initiatives.

Investors continue to monitor whether commercial agreements, regulatory progress and healthcare adoption can translate into sustained revenue growth.

Factors investors generally monitor

4DMedical’s performance is influenced by healthcare adoption, regulatory outcomes, reimbursement pathways, clinical validation and commercial execution.

Commercial adoption remains a key consideration for medical technology companies. Investors generally monitor the number of healthcare sites using products, scan volumes, customer retention and revenue generated from commercial deployments.

Regulatory approvals and reimbursement pathways are also important. Healthcare technologies often require regulatory clearance and reimbursement support before achieving wider adoption.

Clinical validation plays a significant role in medical imaging. Studies demonstrating the effectiveness and usefulness of technology can support adoption among healthcare providers and research organisations.

Partnerships with hospitals, imaging providers and pharmaceutical companies are another focus area. These relationships can expand market access and create additional revenue opportunities.

Cash management remains relevant for companies investing in healthcare technology development. Investors assess how businesses balance commercial expansion, research Investment and operating costs.

Understanding the share price movement

4DMedical’s 6.07% share price increase on 20 August 2026 may reflect changes in investor sentiment, trading activity or market positioning within the healthcare sector. However, daily share price movements alone do not necessarily represent changes in the company’s underlying fundamentals.

Healthcare technology stocks can experience short-term Volatility as investors reassess commercial progress, regulatory developments and future revenue potential.

For 4DMedical, investors are likely to continue monitoring CT:VQ adoption, healthcare partnerships, global site growth and the company’s ability to convert technology development into recurring commercial revenue.

Conclusion

4DMedical (ASX:4DX) closed at AUD 4.02, up 6.07% on 20 August 2026. The company continues to develop its AI-enabled respiratory imaging platform while expanding commercial activity across healthcare markets.

While the daily share price movement reflects market activity, investors generally assess 4DMedical through broader factors including product adoption, regulatory progress, clinical validation, SaaS site growth and commercial execution. FY26 updates highlighted higher revenue, expanded global deployment and continued progress in bringing respiratory imaging solutions into broader healthcare settings.

FAQs

Q: What was 4DMedical’s share price movement on 20 August 2026?

A: 4DMedical (ASX:4DX) closed at AUD 4.02, up 6.07% on 20 August 2026.

Q: What does 4DMedical do?

A: 4DMedical develops AI-powered respiratory imaging technology designed to provide functional lung insights for healthcare providers and researchers.

Q: What were 4DMedical’s FY26 revenue highlights?

A: 4DMedical reported FY26 operating revenue of AUD 7.2 million, up 23% compared with the prior corresponding period.

Q: What is CT:VQ?

A: CT:VQ is 4DMedical’s respiratory imaging solution designed to provide ventilation and perfusion analysis using computed tomography technology.

Q: What factors influence 4DMedical’s outlook?

A: Investors generally monitor commercial adoption, regulatory progress, reimbursement pathways, healthcare partnerships, scan volumes and recurring revenue growth.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.